Abstract:Aims The risk for cardiovascular-related death is predicted to be higher in individuals with Serious Mental Illness (SMI) due to increased prevalence of common cardiac risk factors like smoking, physical inactivity, poor diet, substance use and hyperlipidemia among them. Methods The aim of this retrospective study was to evaluate the physical health of patients with SMI in various settings- acute inpatient, tertiary care hospital and community. We estimated the cardiovascular disease risk of schizophrenia patients with the aid of Framingham Risk Score (FRS) assessment tool, which can quantitatively predict both the heart age and 10-year CVD Risk percentage of patients aged ≥ 30 years. The clozapine to norclozapine ratio was compared with triglyceride levels, body weight, BMI, and fasting blood glucose in patients after treatment with clozapine. Southlake Regional Health Center's practice was compared with the national standards set by Diabetes Canada 2018 guidelines by conducting a clinical audit. 68 non-diabetic, patients aged ≥ 30 years with all the risk factor records for FRS assessment were selected from a cohort of 183 patients registered in the schizophrenia clinic of Southlake Regional Health Centre. The data were collected from patient records from the 75 patients registered with Assertive Community Treatment Team in Georgina, Ontario. The sample size of the study on inpatients was 49 participants from the acute psychiatry ward consisting of 28 females and 21 males during the month of November 2021. Results Males, on average, were found to have an intermediate 10-year CVD risk (~11.2%; FRS total points: 11.27) in comparison to females who, on average, had a low 10-year CVD risk (~7.3%; FRS total points: 11.19). 26% of the patients using FRS were calculated to be at high risk and 28% with intermediate risk of developing a CVD. The average heart age of the sample patients was 60 years, which was 9 years higher than the total average age (51 years). The investigated biomarkers of Hemoglobin A1C, triglycerides, and glucose serum concentration were examined graphically, separated into categories of the ratio measurements of 0–2, 2–3, and 3+. For all biomarkers, lower values were more desirable. Triglycerides were the lowest in the 3+ ratio category. Hemoglobin A1C and glucose serum concentration were lowest in the 0–2 ratio category.100% of patients with diabetes had their blood sugar levels measured and 66.67% were referred to an endocrinologist. In patients without diabetes, 91.30% had their blood sugar levels measured, 39.13% had their HbA1C levels measured, and 6.52% had neither their HbA1C, nor their blood sugar levels measured. Conclusion Cardiovascular complication can be one of the leading causes of death in the next 10 years among schizophrenia patients due to age, poor lifestyle choices, and current estimations via the FRS assessment tool. Further studies need to be conducted with a larger sample size and more recent data to examine any adverse lifestyle changes in schizophrenia patients during the pandemic, which could have negatively influenced their cardiovascular health. It is recommended that doctors weigh the risks vs benefits of prescribing clozapine to patients with high triglyceride levels.

The relationship of cardiovascular disease risk, clozapine antipsychotic use and cognitive function in a large Chinese schizophrenia cohort

From strict quarantine to an optimized policy: Are we psychologically prepared?

Correlation of Orexin-A and Brain-Derived Neurotrophic Factor Levels in Metabolic Syndrome and Cognitive Impairment in Schizophrenia Treated with Clozapine

Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies.

Sex-specific associations between 10-year cardiovascular risk, clinical symptoms and cognitive impairments in schizophrenia

The Prevalence and Clinical-Demographic Correlates of Diabetes Mellitus in Chronic Schizophrenic Patients Receiving Clozapine.

Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia

Cardiovascular Disease Risk in SMI Across Various Settings in a Semirural Area – a Study During COVID-19 Pandemic

Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort

Cognitive Burden of Anticholinergic Medications in Psychotic Disorders

Cardiometabolic biomarkers and comorbid metabolic syndrome in schizophrenia: A cross-sectional study of long-term clozapine/olanzapine users

Association Of Blood Cell Counts With The Risk Of Olanzapine- Or Clozapine-Induced Dyslipidemia In Chinese Schizophrenia Patients

Electrocardiographic corrected QT interval prolongation and its risk factors in patients with clozapine treatment

Associations between antipsychotics and the risk of incident cardiovascular diseases in individuals with schizophrenia: a nested case-control study

Gender, Age, Smoking Behaviour And Plasma Clozapine Concentrations In 193 Chinese Inpatients With Schizophrenia

Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis

Genetic Risk of Clozapine Induced Leukopenia and Neutropenia: A Genome-Wide Association Study

The effect of clozapine on immune-related biomarkers in schizophrenia patients

Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia

The study of atherosclerosis for carotid arteries and intracranial arteries in chronic schizophrenic patients treated with clozapine for long durations

Differential Effects of Different Antipsychotic Drugs on Cognitive Function in Patients with Chronic Schizophrenia